This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Aspartylglucosaminuria (AGA deficiency)Aspartylglucosaminuria (AGU)

Basic classification information
ICD-10E77.1
Special Copayment Reduction codeV117
Main Korean nameAspartylglucosaminuria
SynonymsAGU, AGA deficiency, Aspartylglucosaminidase deficiency, Aspartylglycosaminuria

Contents

1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Aspartylglucosaminuria (AGU) was first reported in 1966 by Jenner and Pollitt in the UK. They found large amounts of an abnormal compound, aspartylglucosamine (N-acetylglucosaminyl-asparagine), excreted in the urine of two brothers with intellectual disability and distinctive clinical findings, and reported it as a new enzyme deficiency disease of glycoprotein degradation. The name 'aspartylglucosaminuria' reflects the increased excretion of aspartylglucosamine (glycoasparagine) in the urine.

It was subsequently found that the incidence of this disease is markedly higher in Finland than in other countries, and it was classified as part of the 'Finnish disease heritage'. In 1991, the causative enzyme aspartylglucosaminidase (AGA) was purified and cloned, and a single founder mutation (p.C163S, AGU Finnish mutation) was identified in 98% of Finnish patients, simplifying diagnosis and carrier testing. Various variants have been reported outside Finland.

2. Causes

Aspartylglucosaminuria is caused by an inherited deficiency of the lysosomal enzyme aspartylglucosaminidase (or glycosylasparaginase, AGA, EC 3.5.1.26). This enzyme catalyzes the final step in the degradation of N-linked glycoprotein glycans.

During the lysosomal degradation of N-linked glycoproteins, various glycosidases and sulfatases sequentially cleave the glycans, finally leaving aspartylglucosamine (GlcNAc-asparagine), in which N-acetylglucosamine (GlcNAc) is linked to the amino acid asparagine by an N-glycosidic bond. AGA cleaves this final bond, separating asparagine and GlcNAc. When the enzyme is deficient, this substrate (glycoasparagine) accumulates in lysosomes and is excreted in excess in the urine.

The mode of inheritance is autosomal recessive. The disease develops when pathogenic variants of the AGA gene are present on both alleles.

3. Genetics

The AGA gene is located on chromosome 4q34.3 and consists of 9 exons. The mature AGA enzyme is a heterotetramer (alpha2beta2) composed of alpha and beta subunits and is activated by autocatalytic cleavage of the precursor polypeptide. In this autocatalytic cleavage process, the threonine residue corresponding to p.C163 functions as the nucleophilic amino acid of the active site.

In more than 98% of Finnish patients, a single homozygous mutation p.C163S (also called the Finnish-type mutation, a cysteine-to-serine substitution corresponding to p.T206S) is identified. This variant directly interferes with the active-site threonine, making the autocatalytic cleavage reaction impossible and completely abolishing enzyme activity. In patients outside Finland, various variants such as missense, nonsense, and deletions have been reported. The sibling recurrence risk is 25%, and prenatal diagnosis and carrier testing are possible.

4. General epidemiology

Aspartylglucosaminuria is the most common type of glycoprotein storage disease, with a particularly high incidence in Finland. In Finland, the incidence is estimated at about 1 per 18,000–26,000 births, and 1–3 patients are born each year. The estimated total number of patients in Finland is several hundred. In contrast, it is reported very rarely outside Finland.

There is no sex difference, and patients appear normal at birth, with symptoms beginning to appear from age 2–3. In Finland, the disease is widely recognized and the carrier frequency is relatively high (about 1/36), and a national carrier testing program was also implemented. Outside Finland, diagnostic delay is frequent, and the disease is often discovered late, particularly in the course of searching for the cause of intellectual disability.

5. Pathophysiology

N-linked glycoproteins are synthesized in the endoplasmic reticulum (ER), undergo glycan modification, participate in cellular functions, and are then degraded in lysosomes. Within lysosomes, stepwise degradation of glycans is carried out by various glycosidases (mannosidases, hexosaminidases, fucosidases, sialidases, etc.), and the final product is aspartylglucosamine (glycoasparagine), in which asparagine and N-acetylglucosamine are linked by an N-glycosidic bond.

When AGA is deficient, this substrate accumulates in lysosomes, causing lysosomal dysfunction. In the central nervous system in particular, substrate accumulation in neuronal lysosomes leads to neuronal dysfunction and gradual cell death. Lysosomal swelling of nerve cells is seen on electron microscopy, and neuronal loss in the cerebrum and cerebellum causes progressive cognitive decline. Secondarily, impaired autophagy, mitochondrial dysfunction, and neuroinflammation act together to accelerate neurodegeneration.

In somatic tissues, substrate accumulation also occurs in the liver, spleen, connective tissue, and elsewhere, but its clinical importance is lower than in the central nervous system. Abnormalities of connective tissue components appear in the skin, and lax skin is characteristically observed.

6. Symptoms

The clinical course of aspartylglucosaminuria is relatively typical and can be divided into three stages.

Early stage (0–5 years)

Most are normal at birth, and early development is also within the normal range. From around 1–2 years of age, recurrent infections (respiratory infections, otitis media, gastroenteritis) are frequent, and inguinal hernia is sometimes found early. From age 2–3, language development begins to lag behind peers, and motor development also tends to be slightly slow. Distinctive facial features are mild at this stage and easily missed.

Intermediate stage (5–20 years)

On entering school age, learning disabilities and reduced language comprehension and expression become prominent. Cognitive function gradually declines, and intellectual disability becomes clear. Behavioral problems (impulsivity, aggression) may appear. Facial coarsening becomes more pronounced, and lax skin is observed. In adolescence, seizures sometimes appear for the first time.

Late stage (after age 20)

In adulthood, cognitive decline continues, often reaching severe intellectual disability in the 20s–30s. Motor function also gradually declines, and dysphagia, incontinence, and seizures appear. Life expectancy is shorter than that of the general population, but some patients survive into their 40s–50s.

7. Signs

Distinctive facial features

Mild facial coarsening: a low, broad nose, thick lips, widened eyebrows, and slightly large ears are characteristic. It is not as prominent as in Hurler syndrome and often becomes clear only in adulthood. Mild macrocephaly is sometimes present.

Skin findings

Lax skin and thick skin are characteristic. Angiokeratomas have also been reported in some patients. This is thought to be due to abnormalities of skin connective tissue components.

Skeletal system

Mild skeletal abnormalities may be observed radiologically, but they are milder than in MPS. Joint laxity sometimes appears. Inguinal hernia is found relatively early.

Neurological findings

Intellectual disability is the most important neurological finding. Seizures may appear in adolescence to adulthood. Brain MRI shows progressive cerebral atrophy and white matter abnormalities. In the late stage, parkinsonism-like findings (rigidity, bradykinesia) sometimes appear.

Ophthalmology

Lens opacities have been reported in some patients. Corneal opacity is rare.

8. Screening

Newborn screening for aspartylglucosaminuria has been studied in Finland, but no country currently has adopted it as a standard clinical program. Urine oligosaccharide analysis is the key tool for first-line screening. Aspartylglucosamine (2-acetamido-1-(beta-L-aspartamido)-1,2-dideoxy-beta-D-glucose) is markedly increased in patients' urine and can be detected by thin-layer chromatography (TLC) or LC-MS/MS. A characteristic aspartylglucosamine peak is also identified on urine amino acid analysis (HPLC).

In Finland, a carrier screening program was operated in the past, and molecular screening for the founder mutation (p.C163S) is easy. Outside Finland, care must be taken not to miss this disease in children with unexplained intellectual disability, through urine amino acid analysis or oligosaccharide analysis. When clinically suspected—recurrent infections, hernia, mildly distinctive facial features, progressive intellectual disability—urine oligosaccharide analysis and leukocyte AGA enzyme activity testing are performed immediately.

9. Diagnosis

Confirmation is made by demonstrating markedly reduced AGA (aspartylglucosaminidase) activity in leukocytes or cultured fibroblasts. Fluorometry using a fluorogenic substrate (L-aspartyl-beta-glucosylamine or a related substrate) is the standard.

Biochemical tests

Molecular genetic testing

Pathogenic variants are confirmed by AGA gene sequencing (Sanger or NGS panel). In patients of Finnish descent, identification of homozygosity for the p.C163S variant alone is sufficient for diagnosis. In non-Finnish patients, sequencing of all exons is needed.

Neuroimaging and other tests

10. Treatment

There is currently no approved specific treatment for aspartylglucosaminuria, and treatment centers on symptom relief and supportive care.

Hematopoietic stem cell transplantation (HSCT)

Hematopoietic stem cell transplantation has been performed in some cases, and an effect of slowing disease progression has been reported in a small number of patients. In particular, the better the neurological functional status before transplantation, the better the effect of transplantation. However, the available evidence is limited, and the decision should be made carefully considering transplant-related morbidity and mortality.

Supportive care

Treatments under investigation

Enzyme replacement therapy (ERT) has been studied in an animal model (AGU mouse), and a substrate-reducing effect was confirmed, but because of limited passage across the blood–brain barrier, further research is still needed before clinical application. AAV-based gene therapy is also showing promising results in animal models and is under investigation. Molecular chaperone treatment strategies are also being studied.

11. Prognosis

The prognosis of aspartylglucosaminuria is relatively slow-progressing compared with other glycoprotein storage diseases. Most patients survive into their 40s–50s, and some survive longer. However, on entering adulthood, severe intellectual disability progresses, leading to complete dependence on caregivers.

The clinical course is generally fairly predictable. After the 20s, cognitive decline progresses rapidly, and in the 30s–40s independent living becomes nearly impossible. Seizures, dysphagia, recurrent infections, and declining motor function are the main causes of late-stage morbidity. Causes of death are mainly aspiration pneumonia, prolonged seizures, and infectious complications. Early intensive rehabilitation and special education can help extend the period during which function is maintained.

Psychological support for family members and caregivers and connection to social support services play a very important role in maintaining patients' quality of life. It is recommended to establish a transition plan in advance for adulthood so that a social support system is in place.

12. Prevention

As an autosomal recessive disease, primary prevention is based on genetic counseling and prenatal diagnosis. The recurrence risk for siblings of patients is 25%, and carrier testing of parents is important. In Finland, carrier testing for the founder mutation (p.C163S) is simple and reliable, so prenatal diagnosis can easily be offered to carrier couples. Outside Finland, molecular genetic prenatal diagnosis is performed after the familial variant is identified.

Prenatal diagnosis is made by measuring AGA enzyme activity in fetal cells or by molecular analysis of the AGA gene after CVS (at 10–12 weeks of gestation) or amniocentesis (at 16–18 weeks of gestation). Preimplantation genetic diagnosis (PGT-M) is also an option when the familial variant has been identified. After early diagnosis, early educational intervention, connection to special education programs, and early start of rehabilitation therapy are important as secondary prevention strategies to maximize developmental potential. In Finland, awareness of this disease is high and it tends to be diagnosed relatively early, but in other countries it should be actively included in the differential diagnosis when investigating the cause of intellectual disability.

13. References

  1. Jenner FA, Pollitt RJ. Large quantities of 2-acetamido-1-(beta-L-aspartamido)-1,2-dideoxyglucose in the urine of mentally retarded siblings. Biochem J. 1967;103(2):48-49P. PMID: 6048583
  2. Isenberg JN, Sharp HL. Aspartylglucosaminuria: psychomotor retardation masquerading as a mucopolysaccharidosis. J Pediatr. 1975;86(5):713-718. PMID: 236500
  3. Ikonen E, Julkunen I, Tollersrud OK, Kalkkinen N, Peltonen L. Lysosomal aspartylglucosaminidase is processed to its active subunits by autocatalytic cleavage. EMBO J. 1993;12(5):2007-2014. PMID: 7682976
  4. Mononen I, Kaartinen V, Williams JC. A fluorometric assay for glycosylasparaginase activity and detection of aspartylglycosaminuria. Anal Biochem.1993;208(2):372-374. PMID: 8452580
  5. Arvio MA, Autio S, Louhiala PJ. Early clinical symptoms and incidence of aspartylglucosaminuria in Finland. Acta Paediatr. 1993;82(6-7):587-589. PMID: 8339703
  6. Arvio P, Autio S, Mononen I. Clinical and biochemical findings in Finnish aspartylglucosaminuria (AGU) patients—a follow-up study. J Inherit Metab Dis. 1993;16(1):98-108. PMID: 8487510
  7. Peltonen L, Ikonen E, Baumann M, Nevanlinna H, Aula P. Identification of the true mutations causing aspartylglucosaminuria in Finnish patients. Am J Hum Genet. 1991;49(4):817-821. PMID: 1897524
  8. Dunder U, Kaartinen V, Valtonen P, et al. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 2000;14(2):361-367. PMID: 10657993
  9. Arvio MA, Mononen I, Savolainen H. Aspartylglucosaminuria: a review. Eur J Pediatr. 1999;158(7):534-538. PMID: 10393499
  10. Martelin E, Parkkola R, Lindsberg PJ, Rinne JO, Nikkinen P, Åberg LE. Neurological progression in adults with aspartylglucosaminuria. J Neurol. 2020;267(7):2094-2102. DOI: 10.1007/s00415-020-09793-5. PMID: 32246256